

In the Specification:

Please enter the attached Sequence Listing to replace the Sequence Listing currently on file.

The first paragraph on page 1 has been amended as follows:

This application is a divisional of co-pending U.S. Application Serial No. 09/953,499 filed September 14, 2001 (now U.S. Patent No. 6,838,554 issued 1/4/05), which is a continuation of, and claims priority under 35 USC §120 to, US Application 09/254,465 filed 3/5/99 (now U.S. Patent No. 6,410,708 issued 6/25/05), which is a continuation of, and claims priority under 35 USC 120 to, PCT Application PCT/US98/24855 filed 11/20/98 which claims priority under 35 USC § 119 to US Provisional Application 60/066,364 filed 11/21/97, and where PCT Application PCT/US98/24855 is also-a continuation-in-part of PCT/US98/19437 filed 9/17/98, the disclosures of which are expressly incorporated herein by reference.

The paragraph starting at page 7, line 36 has been amended as follows:

Figures 1A and 1B show a comparison between the polypeptides encoded by A33 antigen (SEQ ID NO: 6), DNA40628 (SEQ ID NO: 1), DNA45416 (SEQ ID NO: 2), DNA35638 (SEQ ID NO: 9) and JAM (SEQ ID NO: 10).

The paragraph starting at page 8, line 20 has been amended as follows:

Figures 9A and 9B shows show a double stranded representation of the DNA42257 (consen02) (SEQ ID NO: 5) along with the locations of five oligonucleotide primers, shown in underline, all used in the isolation of DNA45416 (SEQ ID NO: 7). The oligonucleotides depicted are: 42257.f1 (SEQ ID NO: 18), 42257.f2 (SEQ ID NO: 19), 42257.r1 (SEQ ID NO: 20); 42257.r2 (SEQ ID NO: 21) and 42257.p1 (SEQ ID NO: 22).

The paragraph starting at page 8, line 24 has been amended as follows:

Figures 10A and 10B describes describe the Blast score, match and percent homology alignment between 2 overlapping fragments of DNA40628 and A33_HUMAN, a human A33 antigen precursor. Figure 10A compares the coded residues beginning at nucleotide position 121

to 816 of DNA40628 (SEQ ID NO: 23) with the coded residues beginning at nucleotides 17 to 284 of A33_HUMAN (SEQ ID NO: 24); Figure 10B compares the coded residues beginning at nucleotides 112 to 810 (SEQ ID NO: 25) with the coded residues beginning at nucleotides 12 to 284 (SEQ ID NO: 26), respectively.

The paragraph starting at page 68, line 34 has been amended as follows:

These deposits were made under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure and the Regulations there under (Budapest Treaty). This assures maintenance of a viable culture of the deposit for 30 years from the date of deposit and for at least five (5) years after the most recent request for the furnishing of a sample of the deposit received by the depository. The deposits will be made available by ATCC under the terms of the Budapest Treaty, and subject to an agreement between Genentech, Inc. and ATCC, which assures that all restrictions imposed by the depositor on the availability to the public of the deposited material will be irrevocably removed upon the granting of the pertinent U.S. patent, assures permanent and unrestricted availability of the progeny of the culture of the deposit to the public upon issuance of the pertinent U.S. patent or upon laying open to the public of any U.S. or foreign patent application; whichever comes first, and assures availability of the progeny to one determined by the U.S. Commissioner of Patents and Trademarks to be entitled thereto according to 35 USC § 122 and the Commissioner's rules pursuant thereto (including 37 CFR § 1.14 with particular reference to 886 OG 638).